達比加群酯，≥99％
| ??【編號】：129995 ??【產品名稱】：達比加群酯，≥99％ ??【規格】：5MG ??【用途】：   達比加群酯，≥99％
Product Name： Dabigatran Etexilate
別名：(E)-ethyl 3-(2-((4-(N'-(hexyloxycarbonyl)carbamimidoyl)phenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate
CAS號：211915-06-9
分子式：C34H41N7O5
分子量：627.73
貯存： 儲存溫度-20°C
可溶性：
DMSO 126 mg/mL
Water <1 mg/mL
Ethanol 12 mg/mL
生化和生理學機理：
Description：
IC50 Value： 4.5nM (Ki); 10nM(Thrombin-induced platelet aggregation) [1]
Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) undergoing advanced clinical development as its orally active prodrug,dabigatran etexilate.
in vitro： Dabigatran selectively and reversibly inhibited human thrombin(Ki： 4.5 nM) as well as thrombin-induced platelet aggregation (IC(50)： 10 nM), while showing no inhibitory effect on other platelet-stimulating agents.Thrombin generation in platelet-poor plasma (PPP), measured as the endogenous thrombin potential (ETP) was inhibited concentration-dependently (IC(50)： 0.56 microM). Dabigatran demonstrated concentration-dependent anticoagulant effects in various species in vitro, doubling the activated partial thromboplastin time (aPTT), prothrombin time (PT) and ecarin clotting time (ECT) in human PPP at concentrations of 0.23, 0.83 and 0.18 microM, respectively [1].
in vivo： Dabigatran prolonged the aPTT dose-dependently after intravenous administration in rats (0.3, 1 and 3 mg/kg) and rhesus monkeys (0.15, 0.3 and 0.6 mg/kg). Dose- and time-dependent anticoagulant effects were observed with dabigatran etexilate administered orally to conscious rats (10, 20 and 50 mg/kg) or rhesus monkeys (1, 2.5 or 5 mg/kg), with maximum effects observed between 30 and 120 min after administration, respectively [1]. Patients treated with dabigatran etexilate experienced fewer ischaemic strokes (3.74 dabigatran etexilate vs 3.97 warfarin) and fewer combined intracranial haemorrhages and haemorrhagic strokes (0.43 dabigatran etexilate vs 0.99 warfarin) per 100 patient-years [2].www.atcc360.com
Clinical trial： An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients . Phase1
|
| 上一篇：多尼培南水合物，≥99％ | 下一篇：地奈德，≥99％ |
|---|
熱銷產品 新品上架
產品推薦 相關產品